Skip to content
Kalpvruksh Markets
Offline Log in

ADVENZYMESNSEOffline

ADVANCED ENZYME · INE837H01020 · Small Cap · #915
284.30+5.90 (+2.12%)last close · 05 Nov 2026
Prev close
278.40
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
₹3,560 cr
52-week range · to 05 Nov 2026248.35392.1

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

ADVENZYMES is 27% below its 52-week high, below its 200-day average — a Small Cap company, #915 by market cap.NSE prices to 05 Nov 2026 · a description of the data, not advice

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • above its 20 / 50-day averages · below its 200-day average · 27% below its 52-week high
  • −12.7% vs Nifty 500
  • traded value 1.7× usual · delivery 48% vs 57% usual
  • FPI −0.1 pp · DII −2.9 pp · MF schemes in Sept 2026: 2 bought, 5 cut · no promoter pledge · quarter ended 2026-09-30
  • nothing scheduled or restricting

How big is it?

six-month average market cap

Market capitalisation
₹3,560 cr
Rank
#915
Cap band
Small Cap
Nearest cut-off — Mid / Small
−89.59% from ₹34,190 cr
Clear of the cut-off

Our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page.

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
1.2×
median 1,16,522
Delivered
1,35,841
Of volume
58%

Price & trend

Returns

to 05 Nov 2026

PeriodStockvs Nifty 500vs its industry
1 week+7.6%+1.7 pts—
1 month+4.1%−0.5 pts—
3 months−14.6%−12.7 pts—
6 months−20.1%−20.4 pts—
1 year−8.4%−5.9 pts—

Points = the stock’s return minus the benchmark’s. Prices adjusted for splits and bonuses.

Averages & movement

vs 20-day average
+7.1%
above
vs 50-day average
+1.3%
above
vs 200-day average
−7.9%
below
ATR (14)
4.3%
typical daily range
Volatility
36%
1 month, annualised
Beta
1.16
vs Nifty 500, 1 year
Traded value
1.7×
vs usual
Delivery
48%
usual 57%
From the 52-week high
−27.5%
place in range 25% (0 = at the low)

Ownership

Who owns the company

% of all shares, by quarter

GroupDec 25Mar 26Jun 26Sep 26
Promoters43.0%43.3% +0.243.2%43.6% +0.3
FPI25.9%25.5% −0.426.7% +1.226.6% −0.1
Mutual funds2.2%1.9% −0.21.8% −0.11.2% −0.6
Other DII3.3%3.5% +0.13.0% −0.50.7% −2.2
Individuals17.4%17.6% +0.116.9% −0.618.7% +1.7
Others8.2%8.3% +0.18.3% +0.19.2% +0.9

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
none
Of all shares
none
Jun 25 noneSep 25 noneDec 25 noneMar 26 noneJun 26 noneSep 26 none

Holders

Sep 26

All shareholders
67,468
Individuals
63,620

Indian passive funds’ stake

2026-06-30

Of free float
0.21%
Of all shares
0.12%
Schemes
9
Days to unwind
0.5
at 100% of volume

1,33,647 shares held by Indian passive mutual-fund schemes. A floor, not the total — foreign ETFs, insurance and EPFO are not counted.

Which funds bought and sold

mutual funds · quarter ended 2026-06-30

Funds holding
13
9 index · 4 active
Bought more
6
Sold some
4
FundSharesChangeDid
Motilal Oswal Nifty Microcap 250 Index Fund-Reg(G)Index−12,175−8.5%sold
ICICI Pru ESG Exclusionary Strategy Fund(G)Active−67,107−7.7%sold
UTI MNC Fund-Reg(IDCW)Active−41,957−4.0%sold

Ranked by how much each fund changed its own position, not by size of trade. Every fund here still holds the company — one that sold out entirely leaves no record to find.

Mutual-fund schemes, month by month

fund houses’ own monthly portfolios

MonthSchemesBought newAddedCutSold outShares heldValue
Sep 26100241−33.2%₹37 cr
Aug 26111321−7.2%₹58 cr
Jul 26110330+3.6%₹67 cr
Jun 26110240−2.3%₹63 cr
May 26110230−3.3%₹76 cr
Apr 26110320−0.1%₹75 cr

Each month against the one before, counting only the fund houses that reported both (45 houses in Sep 26); a split or bonus is divided out first. “Partial” = fewer than five houses reported yet.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Insider trades

SEBI PIT disclosures filed with NSE

Promoter group
No market buy or sell
Directors & KMP
No market buy or sell
Others
No market buy or sell
Latest 36 of 68 disclosures
0 selected
11 Mar 2026Vasant RathiPromotersBuy18,000₹0.54 cr26.69%Market Purchase
09 Mar 2026Vasant RathiPromotersBuy65,000₹1.91 cr26.67%Market Purchase
06 Mar 2026Vasant RathiPromotersBuy55,000₹1.64 cr26.61%Market Purchase
05 Mar 2026Vasant RathiPromotersBuy20,000₹0.59 cr26.57%Market Purchase
06 Feb 2026Vasant RathiPromotersBuy20,000₹0.58 cr26.55%Market Purchase
05 Feb 2026Vasant RathiPromotersBuy37,304₹1.08 cr26.53%Market Purchase
04 Feb 2026Vasant RathiPromotersBuy11,362₹0.33 cr26.50%Market Purchase
03 Feb 2026Vasant RathiPromotersBuy21,334₹0.61 cr26.49%Market Purchase
18 Nov 2025Jayesh SoniPromoter GroupSell25,000₹00.01%Gift
26 Jun 2025Payal Akshay KulkarniPromoter GroupSell3,300₹0.11 cr0.00%Market Sale
26 Mar 2025Vasant RathiPromotersBuy25,000₹0.71 cr33.18%Market Purchase
25 Mar 2025Payal Akshay KulkarniPromoter GroupSell20,000₹00.01%Gift
24 Mar 2025Vasant RathiPromotersBuy1,50,000₹4.37 cr33.16%Market Purchase
20 Mar 2025Kishor Laxminarayan RathiPromoter GroupSell11,00,000₹00.36%Gift
17 Sept 2024Kishor Laxminarayan RathiPromotersBuy40,000₹01.35%Gift

Sums count buys and sells of equity (market and off-market); pledges are listed but not summed. From NSE’s filings: the archive to 2 May 2026, its XBRL filings since (NSE circular NSE/CML/2026/12). A filing describes what was done, not why.

Disclosures & deals

last six months · NSE filings

  • Buyback
    Advanced Enzyme Technologies Limited has informed the Exchange about post Buyback Public Announcement
    02 Nov 2026
  • Buyback
    Advanced Enzyme Technologies Limited has informed the Exchange regarding daily report pursuant to Regulation 15(i) of the Buyback Regulations regarding the equity shares bought-back on October 30, 2026. Total no. of equity shares bought back are 0
    02 Nov 2026
  • Board outcome
    Advanced Enzyme Technologies Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
    02 Nov 2026
  • Buyback
    Advanced Enzyme Technologies Limited has informed the Exchange regarding daily report pursuant to Regulation 15(i) of the Buyback Regulations regarding the equity shares bought-back on October 29, 2026. Total no. of equity shares bought back are 54455
    30 Oct 2026
  • Buyback
    Advanced Enzyme Technologies Limited has informed the Exchange regarding daily report pursuant to Regulation 15(i) of the Buyback Regulations regarding the equity shares bought-back on October 28, 2026. Total no. of equity shares bought back are 64583
    29 Oct 2026
  • Buyback
    Advanced Enzyme Technologies Limited has informed the Exchange regarding daily report pursuant to Regulation 15(i) of the Buyback Regulations regarding the equity shares bought-back on October 27, 2026. Total no. of equity shares bought back are 29115
    28 Oct 2026

Latest shown; 8 in six months on all disclosures.

ADVENZYMES: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Corporate actions

full published history

0 selected
EarlierDividend₹1.35Final24 Jul 202624 Jul 2026
EarlierDividend₹1.2Final23 Jul 202523 Jul 2025
EarlierDividend₹4Interim16 May 202517 May 2025
EarlierDividend₹1.1Final18 Jul 202418 Jul 2024
EarlierDividend₹4Interim17 May 202418 May 2024
EarlierDividend₹1Final04 Aug 202305 Aug 2023
EarlierDividend₹4Interim19 May 202320 May 2023
EarlierDividend₹1Final11 Aug 202212 Aug 2022

8 shown. A falling price on an ex-date is not a loss: a dividend leaves the share as cash and a bonus multiplies the shares held.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.